BTG
SERB acquires BTG to expand its treatment portfolio for unmet medical needs
March 2, 2021Manufacturing and Production BTG, SERB, specialty pharmaceuticals
SERB Specialty Pharmaceuticals has purchased BTG Specialty Pharmaceuticals, a division of Boston Scientific that develops treatments with critical conditions, for …
BTG acquires promising oncology pipeline in Galil Medical takeover
May 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing $84 million, BTG, cryoablation, galil medical, oncology, takeover
BTG (LSE: BTG) has announced that is has agreed to acquire Galil Medical, a leading provider of cryoablation products for …
BTG gets FDA nod
November 29, 2013Sales and Marketing BTG, FDA, Varithena, varicose vein
UK healthcare group BTG has received approval from the FDA for a new type of varicose vein treatment to be …
AstraZeneca and BTG sepsis drug fails
August 8, 2012Research and Development, Sales and Marketing AZD977, AstraZeneca, BTG, CytoFab, sepsis
AstraZeneca’s pipeline has suffered another blow with the troubled company halting development of an investigational sepsis drug following poor Phase …
BTG to buy Biocompatibles
November 19, 2010Research and Development BTG, Biocompatibles
BTG is to pay £156 million to acquire Biocompatibles, the drug-device specialists.Established in 1984 and floated in 1995, Biocompatibles specialises …
UK Biotech: time for bold and affirmative action
January 22, 2009Research and Development, Sales and Marketing BTG, Chris Collins, Christopher Evans, Neuropharm, Plethora, UK, biotech, pharma, strategy
Biotech leaders in the UK say the cash-stricken industry has reached ‘breaking point’, and have made an unprecedented plea for …
Suiters approach Protherics
August 21, 2008Sales and Marketing BTG, Protherics
UK biopharmaceutical company Protherics has received approaches from a number of companies interested in acquiring the biopharmaceutical company. The company …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
